Last reviewed · How we verify

IBU TID

Pfizer · Phase 3 active Small molecule

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Pain and inflammation (acute or chronic), Fever reduction, Rheumatoid arthritis.

At a glance

Generic nameIBU TID
SponsorPfizer
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCOX-1, COX-2
ModalitySmall molecule
Therapeutic areaPain Management, Inflammation
PhasePhase 3

Mechanism of action

IBU TID (ibuprofen three times daily) works by blocking COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammatory responses and pain signaling. By reducing prostaglandin levels, the drug suppresses inflammation at the site of injury or disease and lowers pain perception and body temperature. The three-times-daily dosing regimen is a standard dosing schedule for ibuprofen in pain and inflammation management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: